Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amgen (AMG 337)

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A mid-stage anticancer MET inhibitor drug. The compound is a phase 2 small molecule inhibitor of the cell surface enzyme which stimulates cancer cell scattering, invasion and protection from apoptosis. It is being developed to treat gastric and esophageal cancers.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320
  • United States

Amgen (AMG 337) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Amgen (AMG 337)‘s full profile, request access.

Request full access to PitchBook

Amgen (AMG 337) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Amgen (AMG 337)‘s full profile, request access.

Request full access to PitchBook